打开APP

安进与KimeMed接触以开发阿尔兹海默症生物标记物

  1. KimeMed
  2. 安进
  3. 生物标记物
  4. 阿尔兹海默症

来源:生物谷 2013-10-23 09:11

2013年10月22日讯 /生物谷BIOON/ --制药巨头安进公司与加州生物技术公司KineMed公司合作进行神经变性生物标记物的研发以帮助寻找脑细胞死亡紊乱疾病如阿尔兹海默症的发病机理。根据协议,安进公司将使用KineMed公司的蛋白组学质谱分析平台来分析不同蛋白质对脑部神经变性的贡献。

2013年10月22日讯 /生物谷BIOON/ --制药巨头安进公司与加州生物技术公司KineMed公司合作进行神经变性生物标记物的研发以帮助寻找脑细胞死亡紊乱疾病如阿尔兹海默症的发病机理。根据协议,安进公司将使用KineMed公司的蛋白组学质谱分析平台来分析不同蛋白质对脑部神经变性的贡献。KineMed公司介绍,阿尔兹海默症和帕金森症患者的大脑中都有一些折叠异常的蛋白,搞清楚这些蛋白的动力学因素是解决这些疾病的基础。两家公司希望通过这次合作能够进一步阐明该类疾病的成因。(生物谷Bioon.com)

详细英文报道:

Drug developer Amgen ($AMGN) has reached out to KineMed with an eye on neurodegenerative biomarkers, paying to use the California biotech's platform to ferret out the causes of brain cell-killing disorders like Alzheimer's disease.

Under the deal, Amgen gets the rights to KineMed's mass spectrometry-powered proteomics platform, allowing it to track synthesis and clearance rates of pathogenic proteins in the brain that contribute to neurodegeneration.

Brain-destroying ailments like Alzheimer's, Parkinson's and Huntington's diseases all have something in common: They stem from an accumulation of broken and misfolded proteins in the brain, KineMed said.

"Diagnostic tests have not previously been available that reflect the underlying dynamics of the proteins believed to play a causal role in neurodegeneration," KineMed Vice President Patrizia Fanara said in a statement. "This has been a major obstacle in developing drugs that slow the accumulation of these misfolded proteins."

Now, with KineMed's target-discovery platform in tow, Amgen can develop therapies that attack the root cause of neurodegenerative disease, setting sights on compounds that treat misfangled protein generation and prevent brain cell death.

For Amgen, any resulting program would be a first foray into the high-risk, high-reward world of neurodegenerative disease treatments, as the biotech has no pipeline treatments for Alzheimer's or its relatives.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->